CA3290212A1 - Antigenic peptides for prevention and treatment of b-cell malignancy - Google Patents

Antigenic peptides for prevention and treatment of b-cell malignancy

Info

Publication number
CA3290212A1
CA3290212A1 CA3290212A CA3290212A CA3290212A1 CA 3290212 A1 CA3290212 A1 CA 3290212A1 CA 3290212 A CA3290212 A CA 3290212A CA 3290212 A CA3290212 A CA 3290212A CA 3290212 A1 CA3290212 A1 CA 3290212A1
Authority
CA
Canada
Prior art keywords
prevention
treatment
antigenic peptides
cell malignancy
malignancy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3290212A
Other languages
English (en)
Inventor
Laurent CHENE
Francesco STROZZI
Joao Gamelas MAGALHAES
Guillaume KULAKOWSKI
Original Assignee
Enterome SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterome SA filed Critical Enterome SA
Publication of CA3290212A1 publication Critical patent/CA3290212A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001124—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3290212A 2019-11-15 2020-11-13 Antigenic peptides for prevention and treatment of b-cell malignancy Pending CA3290212A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19306475.5 2019-11-15
EP19306475 2019-11-15
EP2020079257 2020-10-16
EPPCT/EP2020/079257 2020-10-16
CA3153470A CA3153470A1 (en) 2019-11-15 2020-11-13 Antigenic peptides for prevention and treatment of b-cell malignancy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3153470A Division CA3153470A1 (en) 2019-11-15 2020-11-13 Antigenic peptides for prevention and treatment of b-cell malignancy

Publications (1)

Publication Number Publication Date
CA3290212A1 true CA3290212A1 (en) 2026-03-02

Family

ID=75911928

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3290212A Pending CA3290212A1 (en) 2019-11-15 2020-11-13 Antigenic peptides for prevention and treatment of b-cell malignancy
CA3153470A Pending CA3153470A1 (en) 2019-11-15 2020-11-13 Antigenic peptides for prevention and treatment of b-cell malignancy

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3153470A Pending CA3153470A1 (en) 2019-11-15 2020-11-13 Antigenic peptides for prevention and treatment of b-cell malignancy

Country Status (19)

Country Link
US (2) US11759508B2 (https=)
EP (2) EP4357356A3 (https=)
JP (1) JP2023501204A (https=)
CN (1) CN114746112A (https=)
AU (1) AU2020384926B2 (https=)
BR (1) BR112022009100A2 (https=)
CA (2) CA3290212A1 (https=)
DK (1) DK4021487T5 (https=)
ES (1) ES2971929T3 (https=)
FI (1) FI4021487T3 (https=)
HR (1) HRP20240116T1 (https=)
HU (1) HUE065075T2 (https=)
LT (1) LT4021487T (https=)
MX (1) MX2022005704A (https=)
PL (1) PL4021487T3 (https=)
RS (1) RS65262B1 (https=)
SI (1) SI4021487T1 (https=)
SM (1) SMT202400048T1 (https=)
WO (1) WO2021094562A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102622188B1 (ko) 2016-10-07 2024-01-05 엔터롬 에스.에이. 암 치료를 위한 면역원성 화합물
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
US11478538B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
CN112118863B (zh) 2018-04-11 2025-05-30 恩特罗姆公司 用于预防和治疗癌症的抗原肽
JP2025081784A (ja) * 2022-03-01 2025-05-28 ｂｉｔＢｉｏｍｅ株式会社 アミノ酸残基配列を同定するための方法，プログラム及び記録媒体
JP2025526447A (ja) * 2022-07-29 2025-08-13 エルジー・ケム・リミテッド 抗原送達用組換え融合タンパク質およびその使用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
FR2798128B1 (fr) 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
WO2005007673A2 (en) * 2003-07-03 2005-01-27 Rush University Medical Center Immunogenic peptides
SI2119726T2 (en) 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
EP2797634A4 (en) 2011-12-29 2015-08-05 Moderna Therapeutics Inc MODIFIED MRNAS FOR THE CODING OF CELL-PENETRATING POLYPEPTIDES
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
EP3446119A1 (en) * 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
CN106008695A (zh) * 2016-06-19 2016-10-12 苏州普罗达生物科技有限公司 一种关于cd19免疫原多肽及其用途
KR102622188B1 (ko) * 2016-10-07 2024-01-05 엔터롬 에스.에이. 암 치료를 위한 면역원성 화합물
WO2019051001A1 (en) * 2017-09-06 2019-03-14 California Institute Of Technology SIGNALING AND BIFUNCTIONAL RECEPTORS HAVING ANTIGENS (SABR)
WO2019072871A2 (en) * 2017-10-09 2019-04-18 Enterome S.A. MICROBIOTIC SEQUENCE VARIANTS OF ANTIGENIC EPITOPES ASSOCIATED WITH A TUMOR
CN112118863B (zh) * 2018-04-11 2025-05-30 恩特罗姆公司 用于预防和治疗癌症的抗原肽
WO2020072700A1 (en) * 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines

Also Published As

Publication number Publication date
WO2021094562A3 (en) 2021-09-30
ES2971929T3 (es) 2024-06-10
LT4021487T (lt) 2024-02-12
DK4021487T3 (da) 2024-02-12
EP4021487A2 (en) 2022-07-06
JP2023501204A (ja) 2023-01-18
BR112022009100A2 (pt) 2022-07-26
AU2020384926A1 (en) 2022-04-28
WO2021094562A2 (en) 2021-05-20
DK4021487T5 (da) 2024-07-29
US20240033335A1 (en) 2024-02-01
US11759508B2 (en) 2023-09-19
PL4021487T3 (pl) 2024-04-15
RS65262B1 (sr) 2024-03-29
AU2020384926B2 (en) 2025-09-18
EP4357356A3 (en) 2024-07-31
CA3153470A1 (en) 2021-05-20
HUE065075T2 (hu) 2024-04-28
MX2022005704A (es) 2022-06-08
CN114746112A (zh) 2022-07-12
EP4357356A2 (en) 2024-04-24
SI4021487T1 (sl) 2024-03-29
US20220323561A1 (en) 2022-10-13
SMT202400048T1 (it) 2024-03-13
FI4021487T3 (fi) 2024-02-06
HRP20240116T1 (hr) 2024-04-12
EP4021487B1 (en) 2023-12-27

Similar Documents

Publication Publication Date Title
CA3290212A1 (en) Antigenic peptides for prevention and treatment of b-cell malignancy
SI3773689T1 (sl) Antigenski peptidi za preprečevanje in zdravljenje raka
IL279347A (en) Gremlin-1 antagonist for cancer prevention and treatment
EP4047617A4 (en) DIGITAL DEVICE AND APPLICATION FOR MYOPIA THERAPY
AU2019383310B2 (en) Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
IL285807A (en) Immunotherapy for cancer treatment
SG11202006160RA (en) Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer
IL281997A (en) Combined treatment for the treatment of uveal melanoma
IL285458A (en) Combined therapy for the treatment of b-cell malignancies
PT4021487T (pt) Péptidos antigénicos para prevenir e tratar neoplasia maligna de células b
IL288433A (en) Peroxidase-3 activation and immunotherapy for cancer treatment
HK40063884A (en) Combination therapy for treatment of b-cell malignancies
HK40063000A (en) Procaspase-3 activation and immunotherapy for treatment of cancer
HK40083703A (en) Individualized vaccines for cancer treatment and prevention
HK40037676A (en) Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer
HK40066926A (en) Immunotherapy for the treatment of cancer
HK40040059A (en) Gremlin-1 antagonist for the prevention and treatment of cancer
HK40079530A (en) Lurbinectedin in the treatment of malignant mesothelioma
GB201917493D0 (en) methods for the treatment of uveal melanoma
HK40074624A (en) Inhibition of sirp-gamma for cancer treatment
HK40075476A (en) Methods of treatment
HK40066871A (en) Treatment of oncogene-driven cancers
AU2019904888A0 (en) Methods and compositions for treatment of xenoantigens
HK40057116A (en) Peptide therapeutics for the treatment of cancer and uses thereof
HK40074336A (en) Treatment of immune evasive tumors

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL

Effective date: 20251024

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251024

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251024

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251125

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251125

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251125

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251125

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20251205

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20260120

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20260120

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260123

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-2-2-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20260302